StockData
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. (SNOA) stock

SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3081% below fair value
$0.88−0.21 (-19.25%)

Close on Nov 16, 2026Market cap $4.21MP/E –Yield –

Sonoma Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Sonoma Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -10.3%. For fiscal 2026 it was -16.3%, against -24.2% the year before. The highest annual figure on record is 72.3% in fiscal 2017.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2026Mar 31, 2026-16.3%+7.9
FY2025Mar 31, 2025-24.2%+13.8
FY2024Mar 31, 2024-38.0%+0.8
FY2023Mar 31, 2023-38.8%+1.5
FY2022Mar 31, 2022-40.3%−19.1
FY2021Mar 31, 2021-21.2%−2.8
FY2020Mar 31, 2020-18.5%+43.7
FY2019Mar 31, 2019-62.2%+23.8
FY2018Mar 31, 2018-86.0%−158.3
FY2017Mar 31, 201772.3%+180.8
FY2016Mar 31, 2016-108.5%−49.3
FY2015Mar 31, 2015-59.2%−86.5
FY2014Mar 31, 201427.3%+62.5
FY2013Mar 31, 2013-35.1%+22.4
FY2012Mar 31, 2012-57.5%+24.0
FY2011Mar 31, 2011-81.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q1 FY2027CQ2 2026Jun 30, 2026-5.2%+25.8
Q4 FY2026CQ1 2026Mar 31, 2026-10.4%+10.2
Q3 FY2026CQ4 2025Dec 31, 2025-18.8%+7.2
Q2 FY2026CQ3 2025Sep 30, 2025-9.5%+7.5
Q1 FY2026CQ2 2025Jun 30, 2025-30.9%+2.8
Q4 FY2025CQ1 2025Mar 31, 2025-20.7%+10.4
Q3 FY2025CQ4 2024Dec 31, 2024-26.0%+1.6
Q2 FY2025CQ3 2024Sep 30, 2024-17.0%+37.3
Q1 FY2025CQ2 2024Jun 30, 2024-33.7%+7.7
Q4 FY2024CQ1 2024Mar 31, 2024-31.0%+12.4
Q3 FY2024CQ4 2023Dec 31, 2023-27.6%+38.3
Q2 FY2024CQ3 2023Sep 30, 2023-54.3%−23.8
Q1 FY2024CQ2 2023Jun 30, 2023-41.4%−19.1
Q4 FY2023CQ1 2023Mar 31, 2023-43.4%+84.7
Q3 FY2023CQ4 2022Dec 31, 2022-65.9%−33.3
Q2 FY2023CQ3 2022Sep 30, 2022-30.5%−27.9
Q1 FY2023CQ2 2022Jun 30, 2022-22.3%+7.5
Q4 FY2022CQ1 2022Mar 31, 2022-128.1%+41.6
Q3 FY2022CQ4 2021Dec 31, 2021-32.5%−19.4
Q2 FY2022CQ3 2021Sep 30, 2021-2.7%−4.8
Q1 FY2022CQ2 2021Jun 30, 2021-29.8%−34.0
Q4 FY2021CQ1 2021Mar 31, 2021-169.7%−129.4
Q3 FY2021CQ4 2020Dec 31, 2020-13.2%+11.5
Q2 FY2021CQ3 2020Sep 30, 20202.1%+27.5
Q1 FY2021CQ2 2020Jun 30, 20204.2%−11.7
Q4 FY2020CQ1 2020Mar 31, 2020-40.3%+33.3
Q3 FY2020CQ4 2019Dec 31, 2019-24.7%+18.9
Q2 FY2020CQ3 2019Sep 30, 2019-25.4%+31.6
Q1 FY2020CQ2 2019Jun 30, 201915.9%+95.1
Q4 FY2019CQ1 2019Mar 31, 2019-73.5%+56.8
Q3 FY2019CQ4 2018Dec 31, 2018-43.5%+22.3
Q2 FY2019CQ3 2018Sep 30, 2018-57.1%+9.3
Q1 FY2019CQ2 2018Jun 30, 2018-79.1%+12.3
Q4 FY2018CQ1 2018Mar 31, 2018-130.3%−69.9
Q3 FY2018CQ4 2017Dec 31, 2017-65.8%−548.6
Q2 FY2018CQ3 2017Sep 30, 2017-66.4%+3.3
Q1 FY2018CQ2 2017Jun 30, 2017-91.5%–
Q4 FY2017CQ1 2017Mar 31, 2017-60.5%–
Q3 FY2017CQ4 2016Dec 31, 2016482.8%–
Q2 FY2017CQ3 2016Sep 30, 2016-69.7%–

More Sonoma Pharmaceuticals figures

See a number that looks wrong?